Please login to the form below

Not currently logged in
Email:
Password:

alirocumab

This page shows the latest alirocumab news and features for those working in and with pharma, biotech and healthcare.

Alnylam swaps Sanofi for Regeneron as R&D partner

Alnylam swaps Sanofi for Regeneron as R&D partner

that resulted in commercial products including cholesterol therapy Praluent (alirocumab), Dupixent (dupilumab) for atopic dermatitis and rheumatoid arthritis therapy Kevzara (sarilumab).

Latest news

More from news
Approximately 10 fully matching, plus 61 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Sanofi has been adept in this area with its previous access to a PRV for Alirocumab for dyslipidaemia (in partnership with Regeneron who had originally purchased the PRV from Biomarin) for

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration

  • Pharma deals during November 2014 Pharma deals during November 2014

    In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9 inhibitor alirocumab, being developed in partnership with Sanofi.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics